Remove 2018 Remove HIV Treatment and Prevention Agents Remove Packaging
article thumbnail

Top 20 RNAi Therapeutic Companies Based on 2022 R&D Expenditure

PharmaShots

This drug is currently in multiple P-IIa clinical trials and is being evaluated in combination with other antiviral agents for cHBV. Founded Year: 2018 Total Employees: ~80 Headquarters: California, United States Market Cap: $43.1M It is a subcutaneous RNAi therapeutic designed to reduce HBV viral antigens, including HBsAg.

article thumbnail

Agile, Data-Driven Life Cycle Management for Continuous Manufacturing

ISPE

1 , 4 A Retrospective Journey In 2015, Vertex’s Orkambi was the first approved drug produced under a CM process for the treatment of cystic fibrosis. Vertex continued to invest in CM with two additional approved drugs—Symdeco/Symkevi in 2018 and Trikafta in 2019—with the same indication. Published 24 September 2018. Garcia, D.